Perspective Therapeutics reports 2Q 2026 results, advances toward VMT-α-NET Phase 3
The company reported roughly $237 million in cash and outlined progress across its four radiopharmaceutical programs ahead of a planned Phase 3 trial in neuroendocrine tumors.
SEC filing